DOCSLIB.ORG

Overexpression of CDC25A and CDC25B in Head and Neck Cancers'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overexpression of CDC25A and CDC25B in Head and Neck Cancers' (CANCER RESEARCH57. 2366-2368. June 15, 19971 Advances in Brief Overexpression of CDC25A and CDC25B in Head and Neck Cancers' Daniela Gasparotto, Roberta Maestro, Sara Piccinin, Tamara Vukosavijevic, LUigi Barzan, Sandro Sulfaro, and Mauro Boiocchi2 Dis'ision of Experimental Oncology 1. (‘enirodi Riferimento Oncologico, via Pedemontana Occidentale 12. 33081 As'iano (PN) ID. G., R. M., S. P., T. V., M. B.), and Divisions of Otorhinolaryngology (L B.) and Pathology (S. S.). Pordenone City Hospital. 33/70 Pordenone. Italy Abstract inhibits kinase activity. These phosphorylation sites are conserved among eukaryotes, and their phosphorylation status is controlled by The deregulation of several cell cycle-related genes participates in the antagonistic action of wee! kinase and CDC25 phosphatases (4). neoplastic transformation. Cell cycle progression Is driven by cyclin In human cells, three CDC25 genes, CDC25A, CDC25B, and dependent kinases, which are positively regulated by association with cyclins and negatively regulated by binding to inhibitory subunits. The cDc25c, havebeenisolated(5—7).ThesethreeCDC25genesfunc activity of cydin.dependent kinases is also regulated by the phosphoryl tion at different phases of the cell cycle. CDC25A and CDC2SB are ation status, which is controlled by the antagonistic action of weel kinase expressed throughout the cell cycle with a peak expression in G@3—5 and CDC25 phosphatases. Three CDC25 genes are present in human cells: h after serum stimulation for CDC25A and in both G1-S-phase and G2 CDC25A, cDc2sB, and CDC25C. These three genes function at different for CDC25B (6, 8). CDC25C is predominantly expressed in G2 and phases of the cell cycle. Whereas CDC2SA and CDC2SB are expressed regulates the timing of entry into mitosis (7, 9). throughout the cell cycle, with peak expression in G, for CDC25A and in Several lines of evidence suggest a role for CDC25s as oncogenes. both G1-S-phase and G2 for CDC2SB, CDC25C is predominantly ex CDC25A and CDC25B have been shown to cooperate with either pressed in G2. Several lines of evidence suggest a role for CDC25s as mutated versions of Ha-ras or loss of Rbl in oncogenic transformation oncogenes. CDC25A and CDC2SB cooperate with Ha-ms or loss ofRbl in the oncogenic transformation of rodent fibroblasts. Moreover, they are of murine fibroblasts. The transfected cells can form colonies in soft transcriptional targets of c-myc, and CDC2SA in particular plays an agar and induce the formation of tumors when injected in nude mice important role as a mediator ofmyc functions. On the basis ofthe evidence (10).TheCDC25AandCDC25Bgenesaretranscriptionaltargetsof that CDC25 phosphatases can act as oncogenes, we analyzed the expres the c-myc oncogene, and CDC25A in particular plays an important sion of CDC2SA, CDC2SB, and CDC2SC genes In 20 squamous cell carci role as a mediator of myc-induced cell cycle activation as well as nomas of the head and neck by quantitative reverse transcription-PCR. apoptosis (1 1). Moreover, expression levels and phosphatase activity Our results show that whereas CDC2SC is expressed at a low level with no of CDC25A are strongly induced in fibroblasts by the adenovirus E1A relevant differences between neoplastic tissue and normal mucosa, oncoprotein, indicating that a high level of CDC25A presumably CDC2SA and CDC2SB are overexpressed in a large fraction of tumors. contributes to the ability of EIA to override the checkpoint control Introduction mechanisms during the G1 phase to induce DNA replication (12). Finally, CDC25A and CDC25B are overexpressed in some cancer cell Head and neck cancers are the sixth most common neoplasm in the lines (6) and in 32% of human breast cancers,4 suggesting a role for world (I). They include cancers of different sites, such as the larynx, these genes in neoplastic transformation. pharynx, oral cavity, and tongue, and over 90% of them are In this study, the role of CDC25 genes in head and neck cancer HNSCCs.3 Epidemiological surveys have shown tobacco smoking as development was analyzed by using a highly sensitive quantitative a major risk factor in the development of HNSCCs, but other factors, RT-PCR approach. Moderate or low levels of expression were de such as alcohol consumption and environmental exposure, play a tected for the CDC25C gene, with no relevant differences between synergistic role (2, 3). It is known that cancer arises as a consequence neoplastic tissue and normal mucosa. In contrast, CDC25A and of a series of genetic changes that are followed by clonal expansion of CDC25B were significantly overexpressed in a large fraction of cells through a selective growth advantage. The identification of the tumors, suggesting that a deregulated expression of these CDC25 nature and timing of these changes is critical for the biological phosphatases may play an important role in head and neck cancer understanding of the disease and can provide markers useful for development. diagnosis and prognosis. Accumulating evidence suggests that the deregulation of several Materials and Methods cell cycle-related genes participates in neoplastic transformation. In eukaryotes, cell cycle progression is controlled by a family of en Samples. Twenty squamous cell carcinomas and corresponding normal zymes known as CDKs (4). These enzymes consist of a catalytic mucosa of the upper aerodigestive tract were collected from patients at the City subunit (CDK) that is positively regulated by association with a Hospital of Pordenone. No patient had been treated with chemotherapy or regulatory subunit, known as cyclin, and negatively regulated by radiotherapy before surgery. All tissues were frozen in liquid nitrogen imme binding to inhibitory subunits (p16, p21, p27, and others). The activity diately after surgery and stored at —80°Cuntilextraction of RNA. of CDKs is also regulated by phosphorylation; inhibitory phosphoryl Quantitative PCR Analysis. Total cellular RNA was extracted using the ation of threonine and tyrosine residues in the ATP-binding site guanidinium thiocyanate method (13). Evaluation of gene expression by Northern blot analysis in fresh tumors is often prevented by the fact that insufficient amounts of RNA are recovered from these samples. In addition, Received 3/I 8/97; accepted 4/30/97. accurate analysis of genes expressed at a low level or of large transcripts, like The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with CDC25 mRNAs, requires very high-quality RNAs, because even a small 18 U.S.C. Section 1734 solely to indicate this fact. amount of degradation may impair the quantification of the transcript. To I Supported in part by a grant from the Italian Association for Cancer Research. circumvent these limitations, we adopted a very sensitive and quantitative 2 To whom requests for reprints should be addressed. 3 The abbreviations used are: HNSCC, head and neck squamous cell carcinoma; CDK. cyclin-dependent kinase; RT-PCR, reverse transcription-PCR. 4 K. Galaktionov, personal communication. 2366 Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 1997 American Association for Cancer Research. OVEREXPRESSIONOFCDC25AANDCDC25BIN HEADANDNECKCANCERS PCR-based analysis, competitive RT-PCR (14). In a competitive RT-PCR, a expressionCDC25ATable 2 CDC25 mRNA constantamountof reverse-transcribedRNAis mixedand coamplifiedwith expressionCase expression CDC25B expressionCDC25C fixed amounts of a synthetic competitor that differs from the target cDNA for the presence of a small insertion/deletion or a restriction site, such that the two mucosa)HN2(tumor/normal mucosa) (tumor/normal mucosa)(tumor/normal productsareeasilydistinguishablebygelelectrophoresis.Becauseofthe high 1.21.2HN4 1.5 similarity,the two productsare amplifiedwith the sameefficiency,and the 1.21HN5 4.5 2.20.8HN7 2.5 amount of target cDNA is quantified on the basis of the amount of synthetic 2.5IHNIO 5.5 competitor needed to produce an equivalent PCR signal. Differences in the 3.81.5HN16 3.5 amount of starting RNA as well as in reverse transcriptase efficiency in diverse 3.11.5HN18 5.1 samples are minimized by normalizing data in comparison with the expression 2.52HN2O 10 31.5HN28 5.4 of a housekeeping gene (in the present study, the ribosomal protein 514 gene). 1.51HN3O 3 also evaluated by competitive PCR. The system was standardized comparing 51.2H1N32 10 PCR and Northern blot data obtained from a series of head and neck-derived 3.81.5HN58 8 cell lines that showed different expression levels of CDC25 mRNAs (data not 2.50.7HNl39 12 3.4IHN158 3.6 shown). 5.51.5HN182 4.5 For RT-PCR, 1 @gofRNA was reverse-transcribed in a 20-pi reaction by 20.8HN189 5.2 random hexanucleotide priming using avian myeloblastosis virus reverse tran 2IHNI91 10 scriptase (Promega, Madison, WI) according to the manufacturer's instruc 41.2TC5O 7 1.41TC5I 1.2 tions. 3.51.5TC53 5.1 RNA expression analysis was carried out by a competitive PCR method 41.2Total 1.5 using synthetic competitors that differed from the cDNA of interest by having overexpressing―“Cases%o overexpressing― IO/@@ a small internal insertion. The primers used, the annealing temperature, and the thetumor were considered overexpressing when the ratio between expression in size of amplified fragments are reported in Table 1. The synthetic competitors and expression in normal tissue wa.s 3. were generated by overlap extension (15). The CDC25A synthetic competitor contained a l4-bp insertion between nucleotides 1425 and 1426 [the numera ies/p.g of RNA; CDC25B, (4.0 ±1.0) X 1O@'copies/pg of RNA; and tion is according to Galaktionov et aL (5)]. The competitor for CDC25B CDC25C, (5.0 ± I.2) x lO@copies/@.tg of RNA], and no relevant carried a 20-bp insertion between nucleotides 1266 and 1267 [the numeration difference in the expression level of CDC25A, CDC2SB, or CDC25C is according to Galaktionov et a!. (5)]. The competitor for CDC25C contained was detected among the different samples.
Load more

Recommended publications
  • CDC25B Mediates Rapamycin-Induced Oncogenic Responses in Cancer Cells
    Published OnlineFirst March 10, 2009; DOI: 10.1158/0008-5472.CAN-08-3222 Research Article CDC25B Mediates Rapamycin-Induced Oncogenic Responses in Cancer Cells Run-qiang Chen,1 Qing-kai Yang,1 Bing-wen Lu,2 Wei Yi,1 Greg Cantin,2 Yan-ling Chen,1 Colleen Fearns,3 John R. Yates III,2 and Jiing-Dwan Lee1 Departments of 1Immunology and Microbial Science, 2Chemical Physiology, and 3Chemistry, The Scripps Research Institute, La Jolla, California Abstract expression of PTEN, increased PI3K activity, and increased expression or activation of AKT in advanced prostate cancer Because the mammalian target of rapamycin (mTOR) pathway (8–10). These aberrations also are indicators of a poor prognosis is commonly deregulated in human cancer, mTOR inhibitors, for prostate cancer patients (11, 12). More importantly, long-term rapamycin and its derivatives, are being actively tested in androgen deprivation treatment for prostate cancer patients that cancer clinical trials. Clinical updates indicate that the reinforces the PI3K/AKT pathway also up-regulates mTOR anticancer effect of these drugs is limited, perhaps due to activation in prostate tumor (9, 10). These abovementioned rapamycin-dependent induction of oncogenic cascades by an experimental and clinical data lead to the supposition that mTOR as yet unclear mechanism. As such, we investigated rapamy- inhibitors (rapamycin and its derivatives) should be effective in cin-dependent phosphoproteomics and discovered that 250 treating human cancer. Unfortunately, recent clinical data indicates phosphosites in 161 cellular proteins were sensitive to that rapamycin shows therapeutic potential in only few types of rapamycin. Among these, rapamycin regulated four kinases human cancer: endometrial carcinoma, renal cell carcinoma, and and four phosphatases.
    [Show full text]
  • Bioinformatics-Based Screening of Key Genes for Transformation of Liver
    Jiang et al. J Transl Med (2020) 18:40 https://doi.org/10.1186/s12967-020-02229-8 Journal of Translational Medicine RESEARCH Open Access Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma Chen Hao Jiang1,2, Xin Yuan1,2, Jiang Fen Li1,2, Yu Fang Xie1,2, An Zhi Zhang1,2, Xue Li Wang1,2, Lan Yang1,2, Chun Xia Liu1,2, Wei Hua Liang1,2, Li Juan Pang1,2, Hong Zou1,2, Xiao Bin Cui1,2, Xi Hua Shen1,2, Yan Qi1,2, Jin Fang Jiang1,2, Wen Yi Gu4, Feng Li1,2,3 and Jian Ming Hu1,2* Abstract Background: Hepatocellular carcinoma (HCC) is the most common type of liver tumour, and is closely related to liver cirrhosis. Previous studies have focussed on the pathogenesis of liver cirrhosis developing into HCC, but the molecular mechanism remains unclear. The aims of the present study were to identify key genes related to the transformation of cirrhosis into HCC, and explore the associated molecular mechanisms. Methods: GSE89377, GSE17548, GSE63898 and GSE54236 mRNA microarray datasets from Gene Expression Omni- bus (GEO) were analysed to obtain diferentially expressed genes (DEGs) between HCC and liver cirrhosis tissues, and network analysis of protein–protein interactions (PPIs) was carried out. String and Cytoscape were used to analyse modules and identify hub genes, Kaplan–Meier Plotter and Oncomine databases were used to explore relationships between hub genes and disease occurrence, development and prognosis of HCC, and the molecular mechanism of the main hub gene was probed using Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • Genetic Alterations of Protein Tyrosine Phosphatases in Human Cancers
    Oncogene (2015) 34, 3885–3894 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Genetic alterations of protein tyrosine phosphatases in human cancers S Zhao1,2,3, D Sedwick3,4 and Z Wang2,3 Protein tyrosine phosphatases (PTPs) are enzymes that remove phosphate from tyrosine residues in proteins. Recent whole-exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. Beside PTPN11, which functions as an oncogene in leukemia, genetic and functional studies indicate that most of mutant PTPs are tumor suppressor genes. Identification of the substrates and corresponding kinases of the mutant PTPs may provide novel therapeutic targets for cancers harboring these mutant PTPs. Oncogene (2015) 34, 3885–3894; doi:10.1038/onc.2014.326; published online 29 September 2014 INTRODUCTION tyrosine/threonine-specific phosphatases. (4) Class IV PTPs include Protein tyrosine phosphorylation has a critical role in virtually all four Drosophila Eya homologs (Eya1, Eya2, Eya3 and Eya4), which human cellular processes that are involved in oncogenesis.1 can dephosphorylate both tyrosine and serine residues. Protein tyrosine phosphorylation is coordinately regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases 1 THE THREE-DIMENSIONAL STRUCTURE AND CATALYTIC (PTPs). Although PTKs add phosphate to tyrosine residues in MECHANISM OF PTPS proteins, PTPs remove it. Many PTKs are well-documented oncogenes.1 Recent cancer genomic studies provided compelling The three-dimensional structures of the catalytic domains of evidence that many PTPs function as tumor suppressor genes, classical PTPs (RPTPs and non-RPTPs) are extremely well because a majority of PTP mutations that have been identified in conserved.5 Even the catalytic domain structures of the dual- human cancers are loss-of-function mutations.
    [Show full text]
  • FOXM1 Is a Transcriptional Target of Erα and Has a Critical Role in Breast
    Oncogene (2010) 29, 2983–2995 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE FOXM1 is a transcriptional target of ERa and has a critical role in breast cancer endocrine sensitivity and resistance J Millour1, D Constantinidou1, AV Stavropoulou1, MSC Wilson1, SS Myatt1, JM-M Kwok1, K Sivanandan1, RC Coombes1, RH Medema2, J Hartman3, AE Lykkesfeldt4 and EW-F Lam1 1Department of Surgery and Cancer, Imperial College London, London, UK; 2Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; 3Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden and 4Department of Breast Cancer Research, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark In this study, we investigated the regulation of FOXM1 Introduction expression by estrogen receptor a (ERa) and its role in hormonal therapy and endocrine resistance. FOXM1 Breast cancer is the second most prevalent cause of protein and mRNA expression was regulated by ER- cancer death in the western hemisphere and displays a ligands, including estrogen, tamoxifen (OHT) and fulves- complex aeitology. The forkhead box (FOX) family trant (ICI182780; ICI) in breast carcinoma cell lines. member FOXM1 was previously reported to be elevated Depletion of ERa by RNA interference (RNAi) in MCF-7 in breast cancer as well as in carcinomas of other origins cells downregulated FOXM1 expression. Reporter gene (Pilarsky et al., 2004). FOXM1 is expressed in prolifer- assays showed that ERa activates FOXM1 transcription ating adult tissues and in response to injury or repair through an estrogen-response element (ERE) located (Korver et al., 1997a, b; Ye et al., 1999; Leung et al., within the proximal promoter region.
    [Show full text]
  • The Cdc25b Phosphatase Is Essential for the G2/M Phase Transition in Human Cells
    Journal of Cell Science 111, 2445-2453 (1998) 2445 Printed in Great Britain © The Company of Biologists Limited 1998 JCS3777 The cdc25B phosphatase is essential for the G2/M phase transition in human cells Christiane Lammer1, Sybille Wagerer1, Rainer Saffrich2, Daniel Mertens1, Wilhelm Ansorge2 and Ingrid Hoffmann1,* 1FS 6 Angewandte Tumorvirologie (F0400), Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany 2Biochemical Instrumentation Programme, European Molecular Biology Laboratory, Meyerhofstr. 1, 69117 Heidelberg, Germany *Author for correspondence (e-mail: [email protected]) Accepted 15 June; published on WWW 30 July 1998 SUMMARY Cdc25 phosphatases play key roles in cell cycle progression cdc25B is activated through phosphorylation during S- by activating cyclin-dependent kinases. In human cells, phase. Using a cell duplication, microinjection assay we cdc25 proteins are encoded by a multigene family, show that ablation of cdc25B function by specific antibodies consisting of cdc25A, cdc25B and cdc25C. While cdc25A blocks cell cycle progression in Hs68 cells by inhibition of plays a crucial role at the G1/S phase transition, cdc25C is entry into mitosis. Cdc25B function neither plays a role in involved in the dephosphorylation and activation of the later stages of mitosis nor for the inititation of DNA mitotic kinase, cdc2/cyclinB. In addition, cdc25C itself is replication. These results indicate that cdc25B is a mitotic regulated by cdc2/cyclinB which then creates a positive regulator that might act as a ‘starter phosphatase’ to feedback loop that controls entry into mitosis. In this study initiate the positive feedback loop at the entry into M phase. we show that the activity of cdc25B appears during late S phase and peaks during G2 phase.
    [Show full text]
  • Arylstibonic Acids Are Potent and Isoform-Selective Inhibitors Of
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Spiral - Imperial College Digital Repository Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases Lok Hang Mak a,b, Jessica Knott a,b, Katherine A. Scott c,d, Claire Scott e, Gillian F. Whyte a,b, Yu Ye f, David Mann b,c, Oscar Ces a,b, James Stivers f, Rudiger Woscholski a,b,* a Department of Chemistry, Imperial College London, Exhibition Road, London SW7 2AZ, UK b Institute of Chemical Biology, Imperial College London, Exhibition Road, London SW7 2AZ, UK c Division of Molecular Biosciences, Imperial College London, Exhibition Road, London SW7 2AZ, UK d Drug Discovery Centre, Imperial College London, St Dunstan’s Road, London, W6 8RP, UK e Division of Cell and Molecular Biology, Imperial College London, Exhibition Road, London SW7 2AZ, UK f Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 *Corresponding author: Tel: +44 (0) 2075945305, Email: [email protected] Keywords: Arylstibonic acids, protein tyrosine phosphatase, Cdc25 inhibitor Abstract In this study, a library of arylstibonic acids were screened as potential protein tyrosine phosphatase inhibitors. Two compounds, namely 13778 and P6949 were identified as potent Cdc25 phosphatase inhibitors, an important key regulator of the eukaryotic cell cycle. These arylstibonic acids were also tested against other members of the protein tyrosine phosphatase family and were found to display good specificity and potency for Cdc25 phosphatases. Introduction Phosphatases are important regulators of many cellular functions, which in turn impact disease and human health.
    [Show full text]
  • Loss of the Forkhead Transcription Factor Foxm1 Causes Centrosome Amplification and Mitotic Catastrophe
    Research Article Loss of the Forkhead Transcription Factor FoxM1 Causes Centrosome Amplification and Mitotic Catastrophe Diane R. Wonsey and Maximillian T. Follettie Department of Discovery Medicine, Wyeth Research, Cambridge, Massachusetts Abstract with a targeted deletion of FoxM1 in the liver show decreased Expression of the forkhead transcription factor FoxM1 bromodeoxyuridine (BrdUrd) incorporation and fewer mitotic cells correlates with proliferative status in a variety of normal compared with wild-type controls following partial hepatectomy (6). and transformed cell types. Elevated expression of FoxM1 has Conversely, premature expression of FoxM1 in transgenic mice been noted in both hepatocellular carcinoma and basal cell accelerates hepatocyte DNA replication and the expression of cell carcinoma. However, whether FoxM1 expression is essential cycle regulatory proteins following partial hepatectomy (7). for the viability of transformed cells is unknown. We report Consistent with a role in proliferation, elevated expression of here that the expression of FoxM1 is significantly elevated in FoxM1 has been reported in both basal cell carcinoma (8) and in primary breast cancer. Microarray analysis shows that FoxM1 hepatocellular carcinoma (9). In addition, FoxM1 expression is re- regulates genes that are essential for faithful chromosome quired for the proliferative expansion of hepatocellular carcinoma segregation and mitosis, including Nek2, KIF20A, and CENP-A. in a mouse model of tumor induction (10). The observation that a p19ARF peptide fragment physically interacts with FoxM1, sup- Loss of FoxM1 expression generates mitotic spindle defects, delays cells in mitosis, and induces mitotic catastrophe. Time- presses FoxM1 transcriptional activity, and inhibits FoxM1- lapse microscopy indicates that depletion of FoxM1 generates enhanced anchorage-independent growth (10) suggests that cells that enter mitosis but are unable to complete cell FoxM1 may be an attractive target for cancer therapy.
    [Show full text]
  • Arylstibonic Acids Are Potent and Isoform-Selective Inhibitors of Cdc25a and Cdc25b Phosphatases
    Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases Lok Hang Mak a,b, Jessica Knott a,b, Katherine A. Scott c,d, Claire Scott e, Gillian F. Whyte a,b, Yu Ye f, David Mann b,c, Oscar Ces a,b, James Stivers f, Rudiger Woscholski a,b,* a Department of Chemistry, Imperial College London, Exhibition Road, London SW7 2AZ, UK b Institute of Chemical Biology, Imperial College London, Exhibition Road, London SW7 2AZ, UK c Division of Molecular Biosciences, Imperial College London, Exhibition Road, London SW7 2AZ, UK d Drug Discovery Centre, Imperial College London, St Dunstan’s Road, London, W6 8RP, UK e Division of Cell and Molecular Biology, Imperial College London, Exhibition Road, London SW7 2AZ, UK f Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 *Corresponding author: Tel: +44 (0) 2075945305, Email: [email protected] Keywords: Arylstibonic acids, protein tyrosine phosphatase, Cdc25 inhibitor Abstract In this study, a library of arylstibonic acids were screened as potential protein tyrosine phosphatase inhibitors. Two compounds, namely 13778 and P6949 were identified as potent Cdc25 phosphatase inhibitors, an important key regulator of the eukaryotic cell cycle. These arylstibonic acids were also tested against other members of the protein tyrosine phosphatase family and were found to display good specificity and potency for Cdc25 phosphatases. Introduction Phosphatases are important regulators of many cellular functions, which in turn impact disease and human health. In particular, protein tyrosine phosphatases (PTPs), which counteract the many protein tyrosine kinases involved in cellular signaling, and have a significant role in the development of cancer, diabetes and obesity (1, 2).
    [Show full text]
  • Live-Cell Imaging Rnai Screen Identifies PP2A–B55α and Importin-Β1 As Key Mitotic Exit Regulators in Human Cells
    LETTERS Live-cell imaging RNAi screen identifies PP2A–B55α and importin-β1 as key mitotic exit regulators in human cells Michael H. A. Schmitz1,2,3, Michael Held1,2, Veerle Janssens4, James R. A. Hutchins5, Otto Hudecz6, Elitsa Ivanova4, Jozef Goris4, Laura Trinkle-Mulcahy7, Angus I. Lamond8, Ina Poser9, Anthony A. Hyman9, Karl Mechtler5,6, Jan-Michael Peters5 and Daniel W. Gerlich1,2,10 When vertebrate cells exit mitosis various cellular structures can contribute to Cdk1 substrate dephosphorylation during vertebrate are re-organized to build functional interphase cells1. This mitotic exit, whereas Ca2+-triggered mitotic exit in cytostatic-factor- depends on Cdk1 (cyclin dependent kinase 1) inactivation arrested egg extracts depends on calcineurin12,13. Early genetic studies in and subsequent dephosphorylation of its substrates2–4. Drosophila melanogaster 14,15 and Aspergillus nidulans16 reported defects Members of the protein phosphatase 1 and 2A (PP1 and in late mitosis of PP1 and PP2A mutants. However, the assays used in PP2A) families can dephosphorylate Cdk1 substrates in these studies were not specific for mitotic exit because they scored pro- biochemical extracts during mitotic exit5,6, but how this relates metaphase arrest or anaphase chromosome bridges, which can result to postmitotic reassembly of interphase structures in intact from defects in early mitosis. cells is not known. Here, we use a live-cell imaging assay and Intracellular targeting of Ser/Thr phosphatase complexes to specific RNAi knockdown to screen a genome-wide library of protein substrates is mediated by a diverse range of regulatory and targeting phosphatases for mitotic exit functions in human cells. We subunits that associate with a small group of catalytic subunits3,4,17.
    [Show full text]
  • Estrogen Receptor Phosphorylation Deborah A
    Steroids 68 (2003) 1–9 Review Estrogen receptor phosphorylation Deborah A. Lannigan∗ Center for Cell Signaling, Health Sciences Center, University of Virginia, Hospital West, Room 7041, Box 800577, Charlottesville, VA 22908-0577, USA Received 30 April 2002; accepted 13 June 2002 Abstract Estrogen receptor ␣ (ER␣) is phosphorylated on multiple amino acid residues. For example, in response to estradiol binding, human ER␣ is predominately phosphorylated on Ser-118 and to a lesser extent on Ser-104 and Ser-106. In response to activation of the mitogen-activated protein kinase pathway, phosphorylation occurs on Ser-118 and Ser-167. These serine residues are all located within the activation function 1 region of the N-terminal domain of ER␣. In contrast, activation of protein kinase A increases the phosphorylation of Ser-236, which is located in the DNA-binding domain. The in vivo phosphorylation status of Tyr-537, located in the ligand-binding domain, remains controversial. In this review, I present evidence that these phosphorylations occur, and identify the kinases thought to be responsible. Additionally, the functional importance of ER␣ phosphorylation is discussed. © 2002 Elsevier Science Inc. All rights reserved. Keywords: Estrogen receptor; Phosphorylation; Transcription 1. Overview There are two known ER isoforms, ␣ and ␤, which dif- fer in their ligand specificities and physiological functions This review will focus on the major phosphorylation sites [17–19]. There are also a number of splice variants for each in estrogen receptor ␣ (ER␣) that occur in response to ei- of the isoforms, some of which influence the activity of the ther estradiol or through the activation of second messen- wild type receptor [20–23].
    [Show full text]
  • Expression Profile of Tyrosine Phosphatases in HER2 Breast
    Cellular Oncology 32 (2010) 361–372 361 DOI 10.3233/CLO-2010-0520 IOS Press Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors Maria Antonietta Lucci a, Rosaria Orlandi b, Tiziana Triulzi b, Elda Tagliabue b, Andrea Balsari c and Emma Villa-Moruzzi a,∗ a Department of Experimental Pathology, University of Pisa, Pisa, Italy b Molecular Biology Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy c Department of Human Morphology and Biomedical Sciences, University of Milan, Milan, Italy Abstract. Background: HER2-overexpression promotes malignancy by modulating signalling molecules, which include PTPs/DSPs (protein tyrosine and dual-specificity phosphatases). Our aim was to identify PTPs/DSPs displaying HER2-associated expression alterations. Methods: HER2 activity was modulated in MDA-MB-453 cells and PTPs/DSPs expression was analysed with a DNA oligoar- ray, by RT-PCR and immunoblotting. Two public breast tumor datasets were analysed to identify PTPs/DSPs differentially ex- pressed in HER2-positive tumors. Results: In cells (1) HER2-inhibition up-regulated 4 PTPs (PTPRA, PTPRK, PTPN11, PTPN18) and 11 DSPs (7 MKPs [MAP Kinase Phosphatases], 2 PTP4, 2 MTMRs [Myotubularin related phosphatases]) and down-regulated 7 DSPs (2 MKPs, 2 MTMRs, CDKN3, PTEN, CDC25C); (2) HER2-activation with EGF affected 10 DSPs (5 MKPs, 2 MTMRs, PTP4A1, CDKN3, CDC25B) and PTPN13; 8 DSPs were found in both groups. Furthermore, 7 PTPs/DSPs displayed also altered protein level. Analysis of 2 breast cancer datasets identified 6 differentially expressed DSPs: DUSP6, strongly up-regulated in both datasets; DUSP10 and CDC25B, up-regulated; PTP4A2, CDC14A and MTMR11 down-regulated in one dataset.
    [Show full text]